The supply agreement will see the government receive ten million treatment courses of Paxlovid, pending regulatory approval, starting later in the year and into 2022.
Paxlovid is a combination of PF-07321332 and ritonavir; PF-07321332 blocks the action of a protease that the coronavirus needs to replicate while ritonavir is an antiretroviral used commonly to treat HIV infections that slows the breakdown of PF-07321332, thereby increasing its duration of action.
